CNSP

3.5609.07%
EL

E. Lynne Kelley

Chief Medical Officer

Dr. E. Lynne Kelley, M.D., FACS, is Chief Medical Officer of CNS Pharmaceuticals, Inc. from March 2026. Dr. Kelley was Chief Medical Officer of TISSIUM S.A. from 2025 to April 2026. Dr. Kelley served as Chief Medical Officer at X4 Pharmaceuticals, Inc. since April, 2019 until April 03, 2020. She served as Chief Medical Officer at Histogenics Corporation since July 31, 2018 until January 23, 2019 and she assume responsibility for leading medical affairs strategy and building out the department in anticipation of NeoCart’s potential commercial launch. She has more than 20 years of executive management and surgical experience in medical affairs, clinical operations, regulatory affairs and product development to Histogenics. She served as Chief Medical Officer of Senseonics Holdings, Inc. since January 2016 until 2018. From January 2011 to January 2016, Dr. Kelley was the World Wide Vice President of Medical Affairs Medical Surgical Systems of Becton, Dickinson & Company. Prior to that, Dr. Kelley was the Vice President Medical Director for Kimberly-Clark Health Care Inc. from November 2007 to December 2010. Dr. Kelley served as Vice President and Medical Director for Irving-based Kimberly Clark Corp. From 2005 to 2007, Dr. Kelley served as the medical director for the peripheral interventions and vascular surgery business of Boston Scientific. She has worked as an assistant professor of vascular surgery and radiology at Yale University from 2003 to 2005. She is a board-certified general and vascular surgeon. She has been a recipient of a National Institutes of Health-sponsored research grant at Harvard Medical School and the Marco Polo Fellowship in endovascular surgery at the Hospital Henri Mondor, University Paris XII in Creteil, France. Dr. Kelley received her M.D. from Dartmouth Medical School and her B.A. in Biology from Boston University.

Positions